We develop antibody-based therapies targeting IL1RAP

See our pipeline

Our goal is to treat cancer as well as inflammatory and autoimmune diseases

See our clinical program

Strong results provide support for our development programs

See our company presentation

Oppenheimer 35th Annual Healthcare Life Sciences Conference

Oppenheimer 35th Annual Healthcare Life Sciences Conference

Cantargia presented at Oppenheimer 35th Annual Healthcare Life Sciences Conference, February 11, 2025

Watch the event here

2025-02-07 Interview with Redeye

Interview with Interim CEO Damian Marron

Watch the interview here

2025-02-07 Interview with Redeye

2024-11-20 Redeye Redeye Autoimmune & inflammatory diseases event

2024-11-20 Redeye Redeye Autoimmune & inflammatory diseases event

CSO David Liberg presents at Redeye Autoimmune & inflammatory diseases event

Watch the presentation here

Press releases

2025-03-13 Cantargia to Participate at Van Lanschot Kempen’s Life Sciences Conference

2025-03-12 (R) First patient enrolled in Cantargia’s leukemia study with nadunolimab

2025-03-10 Cantargia’s TRIFOUR phase 2 study investigating nadunolimab in triple negative breast cancer fully recruited

(R) = Regulatory press releases

Analysis

2024-09-09, Redeye analysis of Cantargia

2024-03-18, Redeye analysis of Cantargia

2024-02-21, Redeye analysis of Cantargia

2023-11-13, Redeye analysis of Cantargia

Current corporate presentation

Download the corporate presentation as PDF

Other presentations

2025-02-11, Video, Oppenheimer 35th Annual Healthcare Life Sciences Conference

2025-01-22, Video, Redeye Fight Cancer Event 2025

2024-11-21, Video, BioStock Life Science Summit 2024

2024-11-20, Video, Redeye Autoimmune & inflammatory diseases event

2024-10-30, Video, Økonomisk Ugebrev Life Science Investor Conference, Copenhagen (In Swedish)